Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zhixiang Shen"'
Autor:
Sonja Zweegman, Shanti Natarajan-Amé, Francesco Passamonti, Raajit K. Rampal, Moshe Talpaz, Daobin Zhou, Kelly McCaul, Mary Frances McMullin, Candido E. Rivera, Hiroshi Kawabata, Günther Gastl, H. Joachim Deeg, Heinz Gisslinger, Angela Hamblin, Vincent Ribrag, Reinier Raymakers, John Catalano, P. Mineur, Fabrizio Pane, Giuseppe Saglio, Jean Loup Demory, Josef T. Prchal, Qian Jiang, Kudrat Abdulkadyrov, Emmanuel C. Besa, Richard F. Schlenk, Gary J. Schiller, John T. Reilly, Adam J. Mead, Robert Peter Gale, William Stevenson, Gemma Buck, Kazuma Ohyashiki, Dominique Bordessoule, Mark Drummond, Jianyong Li, Ayalew Tefferi, Ting Liu, Tomoko Hata, Jianhua Zhong, Juan Carlos Hernandez Boluda, Damiano Rondelli, Norio Komatsu, John Mascarenhas, Zhixiang Shen, Timothy Devos, Alessandro M. Vannucchi, Katsuto Takenaka, Randall Brown, Haifa K. Al-Ali, Thomas J. Nevill, Jen Chin Wang, Daniel Tesfa, Jennifer O'Sullivan, Andrew Turner, Guanlin Wang, Galina Salogub, Claire N. Harrison, Dragana Milojkovic, Giovanni Barosi, James W. Vardiman, Peter A. W. te Boekhorst, Ruben A. Mesa, Jan Van Droogenbroeck, Manana Sokolova, Vikas Gupta, Lennart Nilsson, Andrey Zaritskiy, Nikolaos Barkas, Werner Linkesch, Mario Cazzola, Jean-Jacques Kiladjian, Ramon V. Tiu, Kiyoshi Ando, Onima Chowdhury, Emilio Ojeda, Martin Griesshammer, Christian Recher, Alessandro Rambaldi, Francisco Cervantes, Giorgina Specchia
Publikováno v:
Leukemia
for the RESUME trialists 2020, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia . https://doi.org/10.1038/s41375-020-0979-6, https://doi.org/10.1038/s41375-020-0979-6
Chowdhury, O, O’Sullivan, J, Barkas, N, Wang, G, Buck, G, Hamblin, A, Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, McMullin, M F, Zhong, J, Gale, R P, Mead, A J, Catalano, J, Stevenson, W, Gastl, G, Linkesch, W, Van Droogenbroeck, J, Mineur, P, Gupta, V, Turner, A, Nevill, T, Li, J, Shen, Z, Liu, T, Bordessoule, D, Natarajan-Amé, S, Recher, C, Demory, J L, Schlenk, R, Griesshammer, M, Cazzola, M, Saglio, G, Specchia, G, Rambaldi, A, Pane, F, Zweegman, S, te Boekhorst, P, Raymakers, R, Abdulkadyrov, K, Sokolova, M, Salogub, G, Zaritskiy, A, Cervantes, F, Boluda, J C H, Ojeda, E, Tesfa, D, Nilsson, L, Drummond, M, Reilly, J, Harrison, C, Milojkovic, D, Rivera, C, Besa, E, Deeg, H J, Mascarenhas, J, Prchal, J, Tiu, R, Talpaz, M, Wang, J C, Rampal, R, Rondelli, D, McCaul, K, Brown, R, Komatsu, N, Ohyashiki, K, Ando, K, Kawabata, H, Takenaka, K, Hata, T, Vardiman, J & for the RESUME trialists 2021, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia, vol. 35, no. 4, pp. 1197-1202 . https://doi.org/10.1038/s41375-020-0979-6
Leukemia, 35(4), 1197-1202. Nature Publishing Group
for the RESUME trialists 2020, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia . https://doi.org/10.1038/s41375-020-0979-6, https://doi.org/10.1038/s41375-020-0979-6
Chowdhury, O, O’Sullivan, J, Barkas, N, Wang, G, Buck, G, Hamblin, A, Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, McMullin, M F, Zhong, J, Gale, R P, Mead, A J, Catalano, J, Stevenson, W, Gastl, G, Linkesch, W, Van Droogenbroeck, J, Mineur, P, Gupta, V, Turner, A, Nevill, T, Li, J, Shen, Z, Liu, T, Bordessoule, D, Natarajan-Amé, S, Recher, C, Demory, J L, Schlenk, R, Griesshammer, M, Cazzola, M, Saglio, G, Specchia, G, Rambaldi, A, Pane, F, Zweegman, S, te Boekhorst, P, Raymakers, R, Abdulkadyrov, K, Sokolova, M, Salogub, G, Zaritskiy, A, Cervantes, F, Boluda, J C H, Ojeda, E, Tesfa, D, Nilsson, L, Drummond, M, Reilly, J, Harrison, C, Milojkovic, D, Rivera, C, Besa, E, Deeg, H J, Mascarenhas, J, Prchal, J, Tiu, R, Talpaz, M, Wang, J C, Rampal, R, Rondelli, D, McCaul, K, Brown, R, Komatsu, N, Ohyashiki, K, Ando, K, Kawabata, H, Takenaka, K, Hata, T, Vardiman, J & for the RESUME trialists 2021, ' Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide ', Leukemia, vol. 35, no. 4, pp. 1197-1202 . https://doi.org/10.1038/s41375-020-0979-6
Leukemia, 35(4), 1197-1202. Nature Publishing Group
Autor:
Bernardo Garichochea, Judit Demeter, Yuankai Shi, Umberto Vitolo, Enrica Morra, Margarida Marques, Miklos Egyed, Toshiki Uchida, Árpád Illés, Kenichi Ishizawa, Cristina Ligia Cebotaru, Ashis Mukhopadhyay, Masafumi Taniwaki, Sung-Soo Yoon, Cristina-Ligia Truica, Cheol Won Suh, Irina Lysenko, Naokuni Uike, Huaqing Wang, Achiel Van Hoof, Maryna Kyselyova, Osmanov Ea, Andrew Belch, Alexy Kuzmin, Caballero Gabarrón, Steven Van Steenweghen, Sergio Cancelado, Olga Samoilova, Kensei Tobinai, Kiyoshi Ando, Susumu Nakahara, Tatiana Scheider, Massimo Federico, Dmitry Udovitsa, Xiaoyan Ke, Yurii Lorie, Tatsu Shimoyama, Weerasak Nawarawong, Sebastian Grosicki, Gregor Verhoef, Nuriet Khuageva, Suporn Chuncharune, Fritz Offner, Albert Oriol Rocafiguera, Charles Farber, Ernst Späth-Schwalbe, Juliana Pereira, Ting Liu, Lee-Yung Shih, Steven Le Gouill, Miklos Udvardy, Richard Greil, Carmen Cao, Tomohiro Kinoshita, Horia Bumbea, Yasuhito Terui, Eva Gonzalez-Barca, Irina Bulavina, Peter Hu, Francisco Javier Capote, Olga Serduk, Akihiro Tomita, Ilseung Choi, Mahmut Gumus, Udomsak Bunworasate, Adriana Teixeira, Vladimir Merkulov, Yeow Tee Goh, Tadeusz Robak, Huiqiang Huang, Jie Jin, Cristina Ileana Burcoveanu, Halyna Pylypenko, Joaquín Díaz, Herlander Marques, Zoltán Gasztonyi, Vijay Rao Phooshkooru, Gayane Tumyan, Maike De Wit, Ali Khojasteh, Marcelo Capra, Vladimir Lima, Dai Maruyama, Viacheslav Pavlov, Georg Heß, Carmino Antonio De Souza, Zhao Wang, Iryna Kryachok, Amel Mezlini, Galvez Cardenas, Marina Golubeva, Lyudmila Kuzina, Patricia Santi, Remy Gressin, Balkis Meddeb, Xiaonan Hong, David Belada, Bernard De Prijck, Jan Maciej Zaucha, Jiri Mayer, Michinori Ogura, Rumiko Okamoto, Dolores, Irit Avivi, Mario Ojeda-Uribe, Grigoriy B Rekhtman, Jun Zhu, Reyes Arranz, Polina Kaplan, André Bosly, Ann Van De Velde, Kenny Mauricio, Yuri Dunaev, Anatoly Golenkov, Oleg Gladkov, Yoshiharu Maeda, Franco Cavalli, Dina Ben Yehuda, Michele Baccarani, Markus Raderer, Razvan Stoia, Carlos Appiani, Zvenyslava Masliak, Zita Borbenyi, Guiseppe Rossi, Julia Alexeeva, Johannes Drach, Kateryna Vilchevskaya, Georgii Manikhas, Jan Novák, Noppadol Siritanaratkul, Zhixiang Shen, Alexander Suvorov, Michael Crump, Pierre Zachee, Ofer Shpilberg, Sepideh Nemat, Mitsutoshi Kurosawa, Sreejith Nair, Bulent Undar, Govind Babu, Kudrat Abdulkadryrov, Adriana Sheliga
Publikováno v:
The Lancet Oncology. 19:1449-1458
Summary Background In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were c
Autor:
Zhixiang Shen, Jiri Mayer, Sandip Shah, M. Brigid Bradley-Garelik, Charles Chuah, Andreas Hochhaus, Neil P. Shah, Eric Bleickardt, Michele Baccarani, Concepción Boqué, Ricardo Pasquini, Hagop M. Kantarjian, Ted Szatrowski, Jorge E. Cortes, David Shapiro, Hirohisa Nakamae, Beatriz Moiraghi, Manuel Ayala, Chao Zhu, Françoise Huguet
Publikováno v:
New England Journal of Medicine. 362:2260-2270
Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after fa
Autor:
Junmin Li, Li Chen, Hongming Zhu, Jiong Hu, Bing Chen, Xiaoyang Li, Lining Wang, Yunxiang Zhang, Yuhong Ren, Huijin Zhao, Yu Chen, Huiping Sun, Qiusheng Chen, Weili Zhao, Jianqing Mi, Zhixiang Shen, Zhenyi Wang, Zhu Chen, Saijuan Chen
Publikováno v:
Blood. 128:445-445
Background The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has showed advantages over standard ATRA and chemotherapy (CHT) in the treatment of low- and intermediate-risk acute promeylocytic leukemia (APL). However, the fi
Autor:
Graeme N. Smith, Andrey Zaritskey, Yanzhi Hsu, Zhixiang Shen, David A. Rizzieri, Franck E. Nicolini, Giuliana Alimena, Saengsuree Jootar, M. L. Veronese, H. K. Al-Ali
Publikováno v:
Blood. 110:2960-2960
Background: Nilotinib is a novel, oral ATP-competitive inhibitor of BCR-ABL; it is significantly more potent (>30-fold) and selective than imatinib. ENACT is an ongoing multicenter, open-label, expanded-access study for pts with imatinib-resistant/in
Publikováno v:
Blood. 104:4624-4624
Purpose: Rituximab is a chimeric anti-CD20 monoclonal antibody that was the first antibody approved by the FDA in the United States of America and SDA in China for the treatment of B-cell non-Hodgkin’s Lymphoma (NHL). It has shown significant effic